Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19646288 | 0.87 | MAOA (0.42) | BRD4SMN1; SMN2ALDH1A1MAOAMAOB | |
| SCHEMBL16640631 | 0.87 | BRD4 (0.47) | BRD4SMN1; SMN2ALDH1A1MAOAMAOB | |
| SCHEMBL644097 | 0.79 | ALDH1A1 (0.59) | BRD4SMN1; SMN2ALDH1A1MAPK14RAB9A | |
| SCHEMBL25668657 | 0.70 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL9098293 | 0.70 | LTA4H (0.39) | SMN1; SMN2ALDH1A1MAOAMAOBMAPK14 | |
| SCHEMBL25594902 | 0.69 | ALDH1A1 (0.39) | BRD4ALDH1A1MAOAMAOBMAPK14 | |
| SCHEMBL27581445 | 0.69 | LTA4H (0.42) | SMN1; SMN2MAOAMAOBLTA4HNPC1 | |
| SCHEMBL3860037 | 0.68 | LTA4H (0.44) | BRD4LTA4HL3MBTL1PKMTSHR | |
| SCHEMBL3863044 | 0.68 | LTA4H (0.44) | ALDH1A1MAOAMAOBMAPK14LTA4H | |
| SCHEMBL4871665 | 0.66 | BRD4 (0.35) | BRD4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827336-B2 | Radio-pharmaceutical complexes | BAYER AS (NO) | 2017-11-28 | — | — | US | disclosed |
| US-9827336-B2 | Radio-pharmaceutical complexes | BAYER AS (NO) | 2017-11-28 | — | — | US | disclosed |
| US-20150147272-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2015-05-28 | — | — | US | disclosed |
| US-20150110817-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2015-04-23 | — | — | US | disclosed |
| US-20150104385-A1 | RADIO-PHARMACEUTICAL COMPLEXES | ALGETA ASA (NO) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150147272-A1 | RADIO-PHARMACEUTICAL COMPLEXES | HCAR3, TYRO3, HCAR1 | BRD4 4325/4885SMN1; SMN2 4815/4885ALDH1A1 2139/4885 |
| US-20150104385-A1 | RADIO-PHARMACEUTICAL COMPLEXES | CD22, HAVCR2, CD2 | BRD4 3732/4885SMN1; SMN2 3587/4885ALDH1A1 1908/4885 |
| US-20150110817-A1 | RADIO-PHARMACEUTICAL COMPLEXES | TSPO, TK1, HCAR1 | BRD4 3440/4885SMN1; SMN2 4022/4885ALDH1A1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.